Articles dans des revues avec comité de lecture (396)
  1. 205. Bidard, F.-C., Lossignol, D., Larsimont, D., Piccart-Gebhart, M., & Awada, A. (2011). Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis. Annals of oncology, 22(2), 480-482. doi:10.1093/annonc/mdq689
  2. 206. Klastersky, J., & Awada, A. (2011). Prevention of febrile neutropenia in chemotherapy – treated cancer patients: pegylated versus standard myeloid colony stimulating factors. Critical reviews in oncology/hematology, 78, 17-23.
  3. 207. Klastersky, J., Awada, A., Paesmans, M., & Aoun, M. (2011). Febrile neutropenia: : a critical review of the initial management. Critical reviews in oncology/hematology, 78, 185-194. doi:10.1016/j.critrevonc.2010.03.008
  4. 208. Deleporte, A., Dumez, H., Awada, A., Costermans, J., Meeus, M., Berghmans, T., Ould Kaci, M., Juhel, N., Berge, A., Taube, T., & Schöffski, P. (2011). Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors. Journal of clinical oncology, 29(15), 3031.
  5. 209. Aftimos, P., Awada, A., & Gil, T. (2011). mTor inhibition in RCC: proof of concept, clinical use, and future directions. Belgian journal of medical oncology, 5(5), 205-211.
  6. 210. Klastersky, J., Gombos, A., Georgala, A., & Awada, A. (2011). Prevention of neutropenia-related events in elderly patients with haematological cancer. Aging health, 7, 6829-6842.
  7. 211. Huyge, V., Garcia, C., Alexiou, J., Ameye, L., Vanderlinden, B., Lemort, M., Bergmann, P., Awada, A., Body, J.-J., & Flamen, P. (2010). Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clinical oncology, 22(10), 818-827. doi:10.1016/j.clon.2010.05.021
  8. 212. Cortes, J., Vahdat, L., Blum, J., Twelves, C. J., Campone, M., Roche, H., Bachelot, T., Awada, A., Paridaens, R., Goncalves, A., Shuster, D., Wanders, J., Fang, F., Gurnani, R., Richmond, E., Cole, P. E., Ashworth, S., & Allison, M. (2010). Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. Journal of clinical oncology, 28(25), 3922-3928. doi:10.1200/JCO.2009.25.8467
  9. 213. Metzger-Filho, O., Moulin, C., & Awada, A. (2010). Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. Current Clinical Pharmacology, 5(3), 166-177. doi:10.2174/157488410791498716
  10. 214. Metzger-Filho, O., Vora, T. S., & Awada, A. (2010). Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends. Expert opinion on investigational drugs, 19 Suppl 1, S31-S39. doi:10.1517/13543781003730135
  11. 215. Awada, A., & Lacombe, D. (2010). AACR-NCI-EORTC International Conference 2009. Expert review of anticancer therapy, 10(3), 319-320. doi:10.1586/ERA.10.4
  12. 216. Burstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., Abbas, R., Powell, C., Turnbull, K., Vermette, J., Zacharchuk, C., & Badwe, R. (2010). Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of clinical oncology, 28(8), 1301-1307. doi:10.1200/JCO.2009.25.8707
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>